In 2020, the label for Epidiolex in the US was expanded to incorporate therapy of seizures associated with tuberous sclerosis advanced.
ໃນປີ 2020, ປ້າຍ ສໍາ ລັບ Epidiolex ໃນສະຫະລັດໄດ້ຖືກຂະຫຍາຍອອກໄປປະກອບມີການປິ່ນປົວອາການຊັກທີ່ກ່ຽວຂ້ອງກັບສະລັບສັບຊ້ອນໂຣກ sclerosis.